Kymera Therapeutics filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company developing oral small molecule degraders through targeted protein degradation. Its Form 8-K reports cover material events such as operating and financial results, clinical and regulatory disclosures, Regulation FD presentations, collaboration-related updates, and capital-raising arrangements involving common stock.
Proxy and governance filings describe shareholder voting matters, executive compensation, equity awards, board oversight, and bylaw provisions, including forum-selection language. The filing record also identifies KYMR common stock and recurring disclosure areas tied to the company’s pipeline, financing capacity, corporate governance, and public-company reporting obligations.
Kymera Therapeutics (KYMR) Form 4: The Chief Medical Officer reported transactions on 10/15/2025 under a Rule 10b5-1 trading plan dated June 2, 2025. He exercised 28,999 stock options at $1.31 and 22,210 options at $2.08, adding shares via option exercises.
He then sold 29,264 shares at a weighted average price of $60.37, 8,963 at $61.4929, 14,896 at $62.7233, and 6,453 at $63.0868. Following these transactions, he beneficially owned 109,992 shares directly.
Kymera Therapeutics (KYMR): insider transaction — The company’s Chief Medical Officer reported multiple trades on 10/13/2025. The officer exercised stock options for 800 shares at $1.31 and 673 shares at $2.08, then sold 3,114 shares at $60. Following these transactions, the officer directly owned 118,359 shares of common stock. The filing notes these trades were made under a Rule 10b5-1 trading plan dated June 2, 2025. The exercised options were fully vested and remain tied to grants expiring on 10/31/2028 and 05/22/2029.
Kymera Therapeutics (KYMR) director reported a Form 4 for Oct 13, 2025: exercised 5,000 stock options at $10.34 and sold 5,000 common shares at a $59.1898 weighted average price under a Rule 10b5-1 plan dated Sept 20, 2024.
Following these transactions, the filing shows 0 shares directly owned and 0 derivative securities remaining.
Bruce N. Jacobs, Chief Financial Officer of Kymera Therapeutics, reported multiple transactions under a Rule 10b5-1 trading plan adopted September 6, 2024. On 09/17/2025 he acquired 79,220 shares of Kymera common stock at $2.08 (via exercise of options) and sold 79,220 shares at a weighted-average price of $50.0048 (sales executed across prices $49.90–$50.25). After the transactions the filing reports 306,629 shares beneficially owned before the sale and 227,409 shares following the sale. The report discloses two stock option transactions with exercise price $2.08 that were fully vested and exercisable, and notes 523 shares were earlier acquired under the employee stock purchase plan on June 2, 2025.
Form 144 filed for Kymera Therapeutics, Inc. (KYMR) reporting a proposed sale of 79,220 shares of common stock through Morgan Stanley Smith Barney LLC on 09/17/2025. The filing shows the shares were acquired the same day by exercise of stock options from the issuer and were paid in cash. The aggregate market value of the shares at the proposed sale is reported as $3,864,351.60 and the company has 71,497,597 shares outstanding per the form. No other securities sales in the past three months are reported and the filer certifies they do not possess undisclosed material adverse information.
Kymera Therapeutics insider transactions by CEO and director Nello Mainolfi on 09/16/2025: The filing shows the exercise of a fully vested stock option with a $2.08 exercise price that converted into 30,000 shares, and an offsetting sale of 30,000 shares at $49. Following these transactions the reporting person beneficially owned 660,482 shares.
The filing notes these trades were executed under a Rule 10b5-1 trading plan adopted September 6, 2024, and the derivative shares underlying the option are fully vested and exercisable with an expiration date of November 13, 2029.
Kymera Therapeutics (KYMR) Form 144 notice reports a proposed sale of 30,000 common shares. The shares are scheduled to be sold through UBS Financial Services on NASDAQ on 09/16/2025 with an aggregate market value of $1,470,000. The filing states 71,497,597 shares outstanding. The 30,000 shares were acquired on 09/16/2025 by exercise of stock options from the issuer and payment was in cash on the same date. The filer reports no securities sold in the past three months and affirms no undisclosed material adverse information.
Kymera Therapeutics insider grant to Chief Legal Officer The filing shows that Brian Adams, Chief Legal Officer of Kymera Therapeutics (KYMR), was granted 52,500 restricted stock units (RSUs) and a stock option covering 105,000 shares on September 3, 2025. The RSUs vest in four equal annual installments beginning September 3, 2026, subject to continued employment. The option has an exercise price of $43.30, vests 25% on September 3, 2026, with the remainder in 36 equal monthly installments, and expires on September 2, 2035. Following the grants, Mr. Adams directly beneficially owns 52,500 shares from the RSUs and 105,000 option shares reported.
Brian Adams, identified as a Director and Chief Legal Officer, submitted an Initial Statement on Form 3 for Kymera Therapeutics, Inc. (KYMR) reporting the event date 09/03/2025. The filing states that no securities are beneficially owned by the reporting person at the time of this statement. The form is signed by an attorney-in-fact, Bruce Jacobs, and includes an exhibit listing a Power of Attorney. This filing notifies the market of the officer/director's initial Section 16 status while showing there is currently no direct or indirect ownership to disclose.
Kymera Therapeutics, Inc. announced that Chief Legal Officer Ellen Chiniara, J.D. informed the company on August 27, 2025 of her intent to retire from the role, effective September 3, 2025. The company states that her retirement is not due to any disagreement regarding operations, policies, or practices, and she will not receive severance payments or benefits in connection with her departure.
Effective September 3, 2025, Brian R. Adams, J.D. will succeed Ms. Chiniara as Chief Legal Officer. The company also issued a press release on September 3, 2025 announcing the retirement and appointment, which is furnished as an exhibit to this report.